Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) activation in acquired hemostatic dysfunction: a diagnostic challenge.
作者信息
Kim Hyun Kyung
机构信息
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
出版信息
Korean J Hematol. 2010 Dec;45(4):215-6. doi: 10.5045/kjh.2010.45.4.215. Epub 2010 Dec 31.
Abstract
摘要
相似文献
1
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) activation in acquired hemostatic dysfunction: a diagnostic challenge.获得性止血功能障碍中凝血酶激活的纤溶抑制物（TAFI）激活的评估：一项诊断挑战。
Korean J Hematol. 2010 Dec;45(4):215-6. doi: 10.5045/kjh.2010.45.4.215. Epub 2010 Dec 31.
2
Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.正常及获得性止血功能障碍中凝血酶激活的纤溶抑制物的特性研究
Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S69-71. doi: 10.1097/00001721-200306001-00016.
3
Stimulation of thrombin- and plasmin-mediated activation of thrombin-activatable fibrinolysis inhibitor by anionic molecules.阴离子分子对凝血酶和纤溶酶介导的凝血酶可激活纤维蛋白溶解抑制剂激活的刺激作用。
Thromb Res. 2016 Oct;146:7-14. doi: 10.1016/j.thromres.2016.08.015. Epub 2016 Aug 17.
4
Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.凝血酶介导的因子XI激活导致纤溶酶原激活物抑制因子依赖的纤维蛋白溶解抑制。
J Clin Invest. 1997 May 15;99(10):2323-7. doi: 10.1172/JCI119412.
5
Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?凝血酶激活的纤维蛋白溶解抑制剂（TAFI）——凝血酶如何调节纤维蛋白溶解？
Ann Med. 2006;38(6):378-88. doi: 10.1080/07853890600852898.
6
Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.凝血酶激活的纤溶抑制物（TAFI）：更新的叙述性综述。
Int J Mol Sci. 2021 Apr 1;22(7):3670. doi: 10.3390/ijms22073670.
7
Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.原发性甲状腺功能减退症患者的血栓酶激活的纤溶抑制物（TAFI）抗原和活性测定。
Clin Appl Thromb Hemost. 2010 Oct;16(5):568-73. doi: 10.1177/1076029609350890. Epub 2009 Dec 2.
8
9
Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).凝血酶激活的纤维蛋白溶解抑制剂（TAFI，血浆羧肽酶原B、羧肽酶原R、羧肽酶原U）
Thromb Res. 2001 Mar 1;101(5):329-54. doi: 10.1016/s0049-3848(00)00411-4.
10
Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.凝血酶激活的纤维蛋白溶解抑制剂（TAFI）：凝血与纤维蛋白溶解之间的分子联系。
Srp Arh Celok Lek. 2010 Jan;138 Suppl 1:74-8. doi: 10.2298/sarh10s1074m.
引用本文的文献
1
Data supporting the structural and functional characterization of Thrombin-Activatable Fibrinolysis Inhibitor in breast cancer.支持凝血酶激活的纤维蛋白溶解抑制剂在乳腺癌中的结构和功能特征的数据。
Data Brief. 2015 Nov 14;5:981-9. doi: 10.1016/j.dib.2015.10.043. eCollection 2015 Dec.
本文引用的文献
1
Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis.脓毒症患者中活化及失活的凝血酶激活的纤溶抑制物水平升高。
Korean J Hematol. 2010 Dec;45(4):264-8. doi: 10.5045/kjh.2010.45.4.264. Epub 2010 Dec 31.
2
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.缺乏凝血酶激活的纤溶抑制物（TAFI）的小鼠易发生脑血栓和缺血性中风。
PLoS One. 2010 Jul 19;5(7):e11658. doi: 10.1371/journal.pone.0011658.
3
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.前羧肽酶U（TAFI）会增加遗传性血栓形成倾向患者的血栓形成风险。
Thromb Res. 2009 Sep;124(4):427-32. doi: 10.1016/j.thromres.2009.01.005. Epub 2009 Feb 4.
4
Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.凝血酶可激活的纤维蛋白溶解抑制剂与儿童严重脑膜炎球菌感染的严重程度及预后相关。
J Thromb Haemost. 2008 Feb;6(2):268-76. doi: 10.1111/j.1538-7836.2008.02841.x. Epub 2007 Nov 15.
5
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.愈发奇妙：凝血酶激活的纤维蛋白溶解抑制因子（TAFI）检测以及对其分子遗传学、基因调控和生物学作用认识的最新进展
Clin Biochem. 2007 Apr;40(7):431-42. doi: 10.1016/j.clinbiochem.2006.10.020. Epub 2006 Nov 21.
6
Development of ELISAs measuring the extent of TAFI activation.用于测量凝血酶激活的纤溶抑制物（TAFI）激活程度的酶联免疫吸附测定（ELISA）的开发。
Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):423-8. doi: 10.1161/01.ATV.0000199246.08616.98. Epub 2005 Dec 8.
7
Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice.凝血酶激活的纤溶抑制物缺失可保护小鼠免受脓毒症诱导的肝损伤。
J Immunol. 2005 Nov 15;175(10):6764-71. doi: 10.4049/jimmunol.175.10.6764.
8
Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.正常及获得性止血功能障碍中凝血酶激活的纤溶抑制物的特性研究
Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S69-71. doi: 10.1097/00001721-200306001-00016.
9
Inducible carboxypeptidase activity. A role in clot lysis in vivo.
Circulation. 1996 Apr 1;93(7):1328-30. doi: 10.1161/01.cir.93.7.1328.
10
Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.凝血酶激活的纤溶抑制物TAFI的纯化与特性分析
J Biol Chem. 1995 Jun 16;270(24):14477-84. doi: 10.1074/jbc.270.24.14477.
Zotero 插件